Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]
Eur Urol. 2023 Jun;83(6):e165.
doi: 10.1016/j.eururo.2023.03.002.
Epub 2023 Mar 10.
1 Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
2 Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
3 The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
4 Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
5 Core Facility Genomics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
6 Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
7 Laboratory and Department of Urology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Universitat de Barcelona, Barcelona, Spain.
8 Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands.
9 Department of BioMedical Research, University of Bern, Bern, Switzerland; Department of Urology, Hospital Center Biel, Biel, Switzerland.
10 Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
11 Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
12 Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.